Catalin Mihalcioiu

8.3k total citations · 1 hit paper
38 papers, 1000 citations indexed

About

Catalin Mihalcioiu is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Catalin Mihalcioiu has authored 38 papers receiving a total of 1000 indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Oncology, 10 papers in Molecular Biology and 8 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Catalin Mihalcioiu's work include Cancer Immunotherapy and Biomarkers (10 papers), HER2/EGFR in Cancer Research (6 papers) and Colorectal Cancer Treatments and Studies (6 papers). Catalin Mihalcioiu is often cited by papers focused on Cancer Immunotherapy and Biomarkers (10 papers), HER2/EGFR in Cancer Research (6 papers) and Colorectal Cancer Treatments and Studies (6 papers). Catalin Mihalcioiu collaborates with scholars based in Canada, United States and India. Catalin Mihalcioiu's co-authors include Niaz Mahmood, Shafaat A. Rabbani, Marni Wiseman, Erich V. Kliewer, Alain Demers, Zoann Nugent, Michael Smylie, David Hogg, Tina Cheng and Anthony M. Joshua and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer Research.

In The Last Decade

Catalin Mihalcioiu

37 papers receiving 976 citations

Hit Papers

Multifaceted Role of the Urokinase-Type Plasminogen Activ... 2018 2026 2020 2023 2018 100 200 300
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Multifaceted Role of the Urokinase-Type Plasminogen Activator (uPA) and Its Receptor (uPAR): Diagnostic, Prognostic, and Therapeutic Applications
    2018 342 citations Niaz Mahmood, Catalin Mihalcioiu et al. Frontiers in Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Catalin Mihalcioiu Canada 14 422 391 283 179 156 38 1000
Igor Vujic Austria 22 691 1.6× 488 1.2× 102 0.4× 129 0.7× 133 0.9× 50 1.4k
Luigia Stefania Stucci Italy 21 759 1.8× 642 1.6× 255 0.9× 179 1.0× 162 1.0× 46 1.5k
T Castel Spain 20 833 2.0× 554 1.4× 204 0.7× 148 0.8× 75 0.5× 62 1.3k
Gabriela Motyckova United States 13 408 1.0× 995 2.5× 270 1.0× 74 0.4× 175 1.1× 19 1.5k
Carol M. Amato United States 16 368 0.9× 616 1.6× 327 1.2× 42 0.2× 101 0.6× 34 1.0k
Christine M. McMahon United States 18 316 0.7× 1.1k 2.7× 392 1.4× 120 0.7× 113 0.7× 59 1.8k
Xiaoyu Song China 12 127 0.3× 354 0.9× 172 0.6× 139 0.8× 82 0.5× 30 987
Micaela Hernberg Finland 20 680 1.6× 408 1.0× 107 0.4× 76 0.4× 148 0.9× 58 1.1k
Iris Tischoff Germany 16 403 1.0× 422 1.1× 155 0.5× 193 1.1× 164 1.1× 54 1.1k
Riccardo Marconcini Italy 17 1000 2.4× 458 1.2× 202 0.7× 166 0.9× 189 1.2× 48 1.3k

Countries citing papers authored by Catalin Mihalcioiu

Since Specialization
Citations

This map shows the geographic impact of Catalin Mihalcioiu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Catalin Mihalcioiu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Catalin Mihalcioiu more than expected).

Fields of papers citing papers by Catalin Mihalcioiu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Catalin Mihalcioiu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Catalin Mihalcioiu. The network helps show where Catalin Mihalcioiu may publish in the future.

Co-authorship network of co-authors of Catalin Mihalcioiu

This figure shows the co-authorship network connecting the top 25 collaborators of Catalin Mihalcioiu. A scholar is included among the top collaborators of Catalin Mihalcioiu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Catalin Mihalcioiu. Catalin Mihalcioiu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Cheishvili, David, et al.. (2025). The epiMelanoma test enables plasma-based detection of melanoma and prediction of immunotherapy response. Scientific Reports. 15(1). 30710–30710.
2.
Tu, Thai Hien, et al.. (2024). Decreased progenitor TCF1 + T-cells correlate with COVID-19 disease severity. Communications Biology. 7(1). 526–526. 2 indexed citations
3.
Elkrief, Arielle, Siddhartha P. Duttagupta, Nicolas Marcoux, et al.. (2024). 1068P Phase II trial of fecal microbiota transplantation (FMT) plus immune checkpoint inhibition (ICI) in advanced non-small cell lung cancer and cutaneous melanoma (FMT-LUMINate). Annals of Oncology. 35. S707–S708. 11 indexed citations
4.
Mihalcioiu, Catalin, Jiarong Li, Dunarel Badescu, et al.. (2023). Improved platform for breast cancer circulating tumor cell enrichment and characterization with next-generation sequencing technology.. PubMed. 13(1). 25–44. 5 indexed citations
5.
Petrella, Teresa M., Catalin Mihalcioiu, Carolyn Nessim, et al.. (2023). A pilot study of the neoadjuvant use of vemurafenib plus cobimetinib in patients with BRAF-mutant melanoma with palpable lymph node metastases: Survival results.. Journal of Clinical Oncology. 41(16_suppl). 9579–9579. 1 indexed citations
6.
Routy, Bertrand, Corentin Richard, Myriam Benlaïfaoui, et al.. (2022). Characterization of Alistipes montrealensis sp. nov., Isolated from Human Feces of a Patient with Metastatic Melanoma Treated with Immune Checkpoint Inhibitors. SHILAP Revista de lepidopterología. 13(1). 140–151. 3 indexed citations
7.
Mahmood, Niaz, Ani Arakelian, Catalin Mihalcioiu, et al.. (2020). Enhanced Anticancer Effect of a Combination of S-adenosylmethionine (SAM) and Immune Checkpoint Inhibitor (ICPi) in a Syngeneic Mouse Model of Advanced Melanoma. Frontiers in Oncology. 10. 16 indexed citations
8.
Cavallone, Luca, Adriana Aguilar‐Mahecha, Josiane Lafleur, et al.. (2020). Prognostic and predictive value of circulating tumor DNA during neoadjuvant chemotherapy for triple negative breast cancer. Scientific Reports. 10(1). 14704–14704. 65 indexed citations
9.
Ernst, D. Scott, Hannah McConkey, Marcus O. Butler, et al.. (2019). Utilization of real-world data to assess the effectiveness of immune checkpoint inhibitors (ICIs) in elderly patients with metastatic melanoma. Annals of Oncology. 30. v553–v553. 2 indexed citations
10.
Dankner, Matthew, Mathieu Lajoie, Dan Moldoveanu, et al.. (2018). Dual MAPK Inhibition Is an Effective Therapeutic Strategy for a Subset of Class II BRAF Mutant Melanomas. Clinical Cancer Research. 24(24). 6483–6494. 47 indexed citations
11.
Tsui, James Man Git, Catalin Mihalcioiu, & Fabio Cury. (2018). Abscopal Effect in a Stage IV Melanoma Patient who Progressed on Pembrolizumab. Cureus. 10(2). e2238–e2238. 24 indexed citations
12.
Cheishvili, David, Niaz Mahmood, Ani Arakelian, et al.. (2018). DNA methylation signatures of breast cancer in peripheral T-cells. BMC Cancer. 18(1). 574–574. 35 indexed citations
13.
Mahmood, Niaz, Catalin Mihalcioiu, & Shafaat A. Rabbani. (2018). Multifaceted Role of the Urokinase-Type Plasminogen Activator (uPA) and Its Receptor (uPAR): Diagnostic, Prognostic, and Therapeutic Applications. Frontiers in Oncology. 8. 24–24. 342 indexed citations breakdown →
14.
15.
16.
Aguilar‐Mahecha, Adriana, Josiane Lafleur, Carole Seguin‐Devaux, et al.. (2012). Q-CROC-03: A prospective biopsy driven clinical trial to study the mechanisms of resistance to chemotherapy in triple-negative breast cancer patients.. Journal of Clinical Oncology. 30(15_suppl). TPS1139–TPS1139. 1 indexed citations
17.
Agarwal, Surendra Kumar, Vera Hirsh, Jason Agulnik, et al.. (2010). A phase II study of gefitinib (G) versus carboplatin and gemcitabine (CG) in chemotherapy-naïve patients with advanced non-small cell lung cancer (NSCLC) and ECOG performance status (PS) 2.. Journal of Clinical Oncology. 28(15_suppl). e18090–e18090. 2 indexed citations
18.
Smylie, Michael, Ralph Wong, Catalin Mihalcioiu, Chris Lee, & Jean‐François Pouliot. (2006). A phase II, open label, monotherapy study of liposomal doxorubicin in patients with metastatic malignant melanoma. Investigational New Drugs. 25(2). 155–159. 36 indexed citations
19.
Nugent, Zoann, Alain Demers, Marni Wiseman, Catalin Mihalcioiu, & Erich V. Kliewer. (2005). Risk of Second Primary Cancer and Death Following a Diagnosis of Nonmelanoma Skin Cancer. Cancer Epidemiology Biomarkers & Prevention. 14(11). 2584–2590. 49 indexed citations
20.
Demers, Alain, Zoann Nugent, Catalin Mihalcioiu, Marni Wiseman, & Erich V. Kliewer. (2005). Trends of nonmelanoma skin cancer from 1960 through 2000 in a Canadian population. Journal of the American Academy of Dermatology. 53(2). 320–328. 118 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Igor Vujic Breakdown of academic impact, for papers by Luigia Stefania Stucci Breakdown of academic impact, for papers by T Castel Breakdown of academic impact, for papers by Gabriela Motyckova Breakdown of academic impact, for papers by Carol M. Amato Breakdown of academic impact, for papers by Christine M. McMahon Breakdown of academic impact, for papers by Xiaoyu Song Breakdown of academic impact, for papers by Micaela Hernberg Breakdown of academic impact, for papers by Iris Tischoff Breakdown of academic impact, for papers by Riccardo Marconcini
Rankless by CCL
2026